Memory's Alzheimer's drug aces Phase II

Memory Pharmaceuticals has announced a positive Phase II roof-of-concept trial of MEM 3454 in 80 patients with Alzheimer's disease over an eight week treatment period. The primary endpoint of the trial was the change from baseline in the Quality of Episodic Secondary Memory (QESM) factor score of the Cognitive Drug Research (CDR) battery. This is good news for Memory, which announced in mid-October that another drug, MEM 1003, failed a Phase IIa study.

"This data is consistent with our preclinical and Phase 1 results and reinforces our belief that MEM 3454 warrants continued development. We look forward to commencing our Phase IIa trial of MEM 3454 in cognitive impairment associated with schizophrenia in the near term."

- check out this press release for more

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.